

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

**Single Technology Appraisal (STA)
Rituximab for the treatment of relapsed chronic lymphocytic leukaemia**

Response to consultee and commentator comments on the provisional matrix of consultees and commentators (pre-referral)

Version of matrix of consultees and commentators reviewed:					
Provisional matrix of consultees and commentators sent for consultation					
Summary of comments, action taken, and justification of action:					
	<i>Proposal:</i>	<i>Proposal made by:</i>		<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
1.	<i>Please ensure that the UK CLL Forum medics are included in this scoping exercise. They are the UK's experts on CLL, and their omission will invalidate the exercise.</i>	<i>Chronic Lymphocytic Leukaemia Support Association</i>		<i>Added</i>	<i>The UK CLL Forum meets the inclusion criteria and has therefore been added to the matrix as a Professional Group</i>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of rituximab for the treatment of relapsed chronic lymphocytic leukaemia

Issue date: May 2009

2.	<i>The British Committee for Standards in Haematology may represent important stakeholders not currently included in the matrix of consultees and commentators.</i>	<i>Roche Products Ltd</i>		<i>Not included</i>	<i>The British Committee for Standards in Haematology is a sub group of The British Society for Haematology. As per inclusion criteria sub groups are not listed as a separate organisation.</i>
3.	<i>United Kingdom CLL Forum may represent important stakeholders not currently included in the matrix of consultees and commentators.</i>	<i>Roche Products Ltd</i>		<i>Added</i>	<i>The UK CLL Forum meets the inclusion criteria and has therefore been added to the matrix as a Professional Group</i>
4.	<i>National Cancer Research Network Lymphoma Clinical Studies Group may represent important stakeholders not currently included in the matrix of consultees and commentators.</i>	<i>Roche Products Ltd</i>		<i>Added</i>	<i>The National Cancer Research Network has been added to the matrix of Consultees and Commentators. However, subgroups of organisations cannot be added as separate organisations and do not meet the inclusion criteria</i>
5.	<i>National Cancer research Network</i>	<i>NICE Secretariat</i>		<i>Added</i>	<i>This organisation has been identified and added as a research group.</i>

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of rituximab for the treatment of relapsed chronic lymphocytic leukaemia

Issue date: May 2009

National Institute for Health and Clinical Excellence

Response to comments on the provisional matrix of consultees and commentators (pre-referral) for the appraisal of rituximab for the treatment of relapsed chronic lymphocytic leukaemia

Issue date: May 2009